3,897 reports of this reaction
4.1% of all ECULIZUMAB reports
#3 most reported adverse reaction
HAEMOGLOBIN DECREASED is the #3 most commonly reported adverse reaction for ECULIZUMAB, manufactured by Alexion Pharmaceuticals Inc.. There are 3,897 FDA adverse event reports linking ECULIZUMAB to HAEMOGLOBIN DECREASED. This represents approximately 4.1% of all 94,110 adverse event reports for this drug.
Patients taking ECULIZUMAB who experience haemoglobin decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HAEMOGLOBIN DECREASED is moderately reported among ECULIZUMAB users, representing a notable but not dominant share of adverse events.
In addition to haemoglobin decreased, the following adverse reactions have been reported for ECULIZUMAB:
The following drugs have also been linked to haemoglobin decreased in FDA adverse event reports:
HAEMOGLOBIN DECREASED has been reported as an adverse event in 3,897 FDA reports for ECULIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
HAEMOGLOBIN DECREASED accounts for approximately 4.1% of all adverse event reports for ECULIZUMAB, making it one of the most commonly reported side effect.
If you experience haemoglobin decreased while taking ECULIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.